Table 1 Comparative analysis of clinical and serological data in 71 patients with Systemic Lupus Erythematosus (SLE) with early and late onset nephritis
|
Total sample N = 71 |
Early nephritis N = 50 (70. 4%) |
Late nephritis N = 21 (29.6%) | P a | |
|---|---|---|---|---|
| Ethnic background b |
Caucasians 27 Afrodescendants 44 |
Caucasians 16 Afrodescendants 34 |
Caucasians 11 Afrodescendants 10 | 0.64 |
| Median age at SLE diagnosis (years) (IQR) | 26.0 (21.0–38.0) | 27 (21-40.2) | 26 (21.0–37.0) | 0.67 |
| Median age at nephritis diagnosis (years) (IQR) | 30.0 (23.0–42.0) | 27.5 (21. 7-41.0) | 35 (29. 5-43.5) | 0.01 |
| Female gender | 62 (87. 3%) | 43 (84. 3%) | 19 (90. 4%) | 0.71 |
| Tobaco exposure | 8 (11.2%) | 4 (9%) | 4 (19.0%) | 0.22 |
| Malar rash | 30 (42.2%) | 20 (40%) | 10 (47.6%) | 0.55 |
| Discoid lesions | 2 (2.8%) | 0 | 2 (9.5%) | 0.08 |
| Photossensitivity | 48 (67.6%) | 32 (64%) | 16 (76.1%) | 0.72 |
| Oral ulcers | 35 (49.2%) | 24 (48%) | 11 (52. 3%) | 0.73 |
| Articular involvement | 60 (84.5%) | 40 (80%) | 20 (95.2%) | 0.15 |
| Serositis | 18 (25. 3%) | 15 (30%) | 3 (14.2%) | 0.23 |
| Psychosis | 1 (1. 4%) | 0 | 1 (4.7%) | 0.29 |
| Convulsions | 6 (8. 4%) | 6 (12%) | 0 | 0.16 |
| Hemolytic anemia | 8 (11. 4%) | 7 (14.2%) | 1 (4.7%) | 0.42 |
| Leukopenia | 25 (35.2%) | 15 (30%) | 10 (47.6%) | 0.15 |
| Lymphocytopenia | 15 (21.1%) | 11 (22%) | 4 (19.0%) | 1.00 |
| Thrombocytopenia | 2 (2.8%) | 1 (2%) | 1 (4.7%) | 0.50 |
| Anti-Ro (SS-A) | 26 (36.6%) | 19 (38%) | 7 (33. 3%) | 0.70 |
| Anti-La (SS-B) | 10 (14.0%) | 7 (14%) | 3 (14.2%) | 1.00 |
| Anti-RNP | 13 (18. 3%) | 7 (14%) | 6 (28.5%) | 0.14 |
| Anti-Sm | 13 (18. 3%) | 8 (16%) | 5 (23.8%) | 0.50 |
| Positive Coombs | 6 (8. 4%) | 5 (10%) | 1 (4.7%) | 0.66 |
| Rheumatoid factor | 6 (8. 4%) | 6 (12%) | 0 | 0.16 |
| Anticardiolipin IgG | 1 (1. 4%) | 1 (2%) | 0 | 1.00 |
| Anticardiolipin IgM | 2 (2.8%) | 2 (4%) | 0 | 1.00 |
| Lupus anticoagulante | 5 (7.0%) | 3 (6%) | 2 (9.5%) | 0.62 |
| Antiphospholipid antibody syndrome | 5 (7.0%) | 3 (6%) | 2 (9.5%) | 0.62 |